Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Edris Badreddin, the Chief Operating Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), recently sold a significant portion of the company’s common stock. According to a regulatory filing, Badreddin disposed of 20,000 shares on March 3, 2025, amounting to a total transaction value of approximately $1,084,592. The shares were sold at prices ranging from $53.12 to $56.20 per share. The transaction comes amid strong momentum for SWTX, which has gained 26% over the past six months and maintains impressive gross profit margins of 93%. According to InvestingPro analysis, the $3.82B market cap company currently shows a FAIR financial health score.
Following these transactions, Badreddin holds 169,712 shares of SpringWorks Therapeutics. The sales were conducted under a pre-established trading plan adopted on February 29, 2024, in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. For deeper insights into SWTX’s valuation and 10+ additional ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, SpringWorks Therapeutics has received FDA approval for its drug GOMEKLI, aimed at treating neurofibromatosis type 1 with symptomatic plexiform neurofibromas. This approval is a significant milestone for the company, accompanied by a rare pediatric disease priority review voucher valued at approximately $100 million. The approval followed the Phase 2b ReNeu trial results, which showed notable response rates in both adults and children. In addition, Merck (NSE:PROR) KGaA is in advanced discussions to potentially acquire SpringWorks Therapeutics, although no binding agreement has been reached yet. Analysts from TD Cowen have raised the price target for SpringWorks shares to $66, maintaining a "Buy" rating, while Guggenheim has adjusted its price target slightly to $78, also keeping a "Buy" rating. The market has responded positively to these developments, reflecting confidence in the company’s growth potential. SpringWorks recently launched its first drug, Ogsiveo, for treating desmoid tumors, and is awaiting regulatory decisions on mirdametinib for NF1. These developments underscore SpringWorks’ focus on addressing severe rare diseases and cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.